COGT — Cogent Biosciences, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1622229 ·
Last close
$27.85
Market Cap
$4.85B
52W High
$43.73
52W Low
$26.36
ADV30
2,242,779
Next earnings
2026-11-09
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -117,184,000 | -111,426,000 | 832,142,000 | 217,461,000 | 315,884,000 |
| Jun 2026 | 0 | — | -102,638,000 | -96,405,000 | 834,546,000 | 181,172,000 | 302,158,000 |
| Mar 2026 | 0 | — | -103,607,000 | -97,352,000 | 903,006,000 | 241,208,000 | 295,313,000 |
| Dec 2025 | 0 | — | -99,493,000 | -102,492,000 | 937,607,000 | 312,012,000 | 301,236,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-307,545,000
Investing CF
$-499,992,000
Financing CF
$861,527,000
CapEx
$-1,695,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.27
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,382,177,000
Inventory
—
Receivables
—
ST Investments
$611,128,000
EBIT TTM
$-372,001,000
Pretax Income TTM
$-377,179,000
Interest Exp TTM
$5,178,000
Analysts
11
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -333,363,000 | -328,937,000 | 937,607,000 | 301,236,000 | 636,371,000 | -264,444,000 |
| Dec 2024 | 0 | -275,939,000 | -255,859,000 | 327,898,000 | 71,612,000 | 256,286,000 | -207,791,000 |
| Dec 2023 | 0 | -208,130,000 | -192,410,000 | 313,437,000 | 55,635,000 | 257,802,000 | -153,624,000 |
| Dec 2022 | 0 | -147,839,000 | -140,241,000 | 300,810,000 | 45,075,000 | 255,735,000 | -118,638,000 |
TTM Snapshot
Revenues TTM
$24,433,000
NetIncome TTM
$-377,179,000
OpCashFlow TTM
—
Assets (Latest)
$834,546,000
Forward EPS
$-1.27
Max Pain — expiry 2027-01-15
max pain strike: $30.00 · spot: $27.81 · call oi: 9,363 · put oi: 1,168
Expected Move to 2027-01-15:
±$6.88
(24.72%) —
implied range
$20.93 –
$34.68
· ATM straddle on $28.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ERAS | Erasca, Inc. | $4.87B | $13.89 | — |
| DNTH | Dianthus Therapeutics, Inc. /DE/ | $4.90B | $86.98 | — |
| TVTX | Travere Therapeutics, Inc. | $4.91B | $51.10 | — |
| GIKLY | Grifols SA | $4.69B | $5.55 | — |
| PTCT | PTC THERAPEUTICS, INC. | $5.04B | $60.36 | — |
News headlines (Yahoo Finance, 1h cache)
Cogent Biosciences (COGT) Stock Looks Fully Priced Against Its Asset Base
2026-11-18 02:17 · Yahoo
Cogent Biosciences (COGT) Faces A Valuation Test As FDA Decisions Draw Closer
2026-11-06 10:14 · Yahoo
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2026 Financial Results
2026-11-05 21:01 · Yahoo
Cogent Biosciences (COGT) Nears Three FDA Decisions. What Is Its Pipeline Worth?
2026-10-20 16:32 · Yahoo
Cogent Biosciences (COGT) Stock Trades At A Premium As FDA Accepts NDA
2026-09-25 10:10 · Yahoo
Cogent Biosciences (COGT) Looks Fully Valued Following FDA NDA Acceptance
2026-09-24 18:12 · Yahoo
Will FDA’s Streamlined Bezuclastinib Review in ASM Change Cogent Biosciences’ (COGT) Narrative?
2026-09-24 12:11 · Yahoo
Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
2026-09-15 12:00 · Yahoo
Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM)
2026-06-30 12:00 · Yahoo
Is Cogent Biosciences (COGT) ’s New Cancer Drug 100 Times More Precise Than What’s Already on the Market?
2026-06-22 14:14 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.